Equities researchers at Ladenburg Thalmann Financial Services began coverage on shares of BeiGene, Ltd. (NASDAQ:BGNE) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $81.00 price target on the stock. Ladenburg Thalmann Financial Services’ price objective would indicate a potential upside of 3.32% from the stock’s previous close.

BGNE has been the subject of a number of other reports. Maxim Group set a $52.00 price target on shares of BeiGene and gave the stock a “buy” rating in a research note on Friday, April 21st. William Blair reissued an “outperform” rating on shares of BeiGene in a research note on Thursday, June 1st. Morgan Stanley reissued an “overweight” rating and set a $83.00 price target on shares of BeiGene in a research note on Monday, July 10th. Zacks Investment Research raised shares of BeiGene from a “sell” rating to a “buy” rating and set a $79.00 price target for the company in a research note on Tuesday, July 11th. Finally, Robert W. Baird boosted their price target on shares of BeiGene from $44.00 to $58.00 and gave the stock an “outperform” rating in a research note on Thursday, July 6th. Seven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $74.80.

Shares of BeiGene (NASDAQ BGNE) opened at 78.40 on Monday. The company’s 50-day moving average is $62.71 and its 200-day moving average is $44.03. BeiGene has a one year low of $26.42 and a one year high of $79.89. The company’s market capitalization is $3.11 billion.

ILLEGAL ACTIVITY WARNING: “BeiGene, Ltd. (NASDAQ:BGNE) Research Coverage Started at Ladenburg Thalmann Financial Services” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/09/beigene-ltd-nasdaqbgne-research-coverage-started-at-ladenburg-thalmann-financial-services.html.

In related news, CEO John Oyler sold 98,500 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $44.16, for a total transaction of $4,349,760.00. Following the completion of the transaction, the chief executive officer now owns 88,535 shares in the company, valued at $3,909,705.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Xiaodong Wang sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $72.44, for a total transaction of $1,448,800.00. Following the transaction, the director now owns 16,300 shares of the company’s stock, valued at approximately $1,180,772. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 389,249 shares of company stock valued at $22,594,820.

A number of hedge funds and other institutional investors have recently modified their holdings of BGNE. SG Americas Securities LLC purchased a new position in shares of BeiGene during the second quarter worth about $111,000. Renaissance Technologies LLC purchased a new position in shares of BeiGene during the first quarter worth about $238,000. Airain ltd purchased a new position in shares of BeiGene during the first quarter worth about $320,000. ProShare Advisors LLC boosted its position in shares of BeiGene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock worth $361,000 after buying an additional 2,918 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its position in shares of BeiGene by 59.1% in the first quarter. Parametric Portfolio Associates LLC now owns 10,796 shares of the company’s stock worth $395,000 after buying an additional 4,010 shares in the last quarter. Hedge funds and other institutional investors own 43.85% of the company’s stock.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.